Knight Therapeutics ( (KHTRF) ) has released its Q2 earnings. Here is a breakdown of the information Knight Therapeutics presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring, in-licensing, and commercializing pharmaceutical products for Canada and Latin America. The company operates through its subsidiaries United Medical, Biotoscana Farma, and Laboratorio LKM. Knight Therapeutics Inc.’s shares trade on the Toronto Stock Exchange under the symbol GUD.
In its second quarter of 2025, Knight Therapeutics reported a record-high quarterly revenue of $107.4 million, marking a 12% increase compared to the same period last year. Despite the revenue growth, the company faced a net loss of $12.6 million, which was significantly higher than the $1.9 million net loss in the previous year. The company also increased its financial guidance for 2025, expecting revenues between $410 million to $420 million.
Key financial highlights include a gross margin of 42%, down from 50% in the previous year, primarily due to hyperinflation accounting in Argentina. The company’s adjusted EBITDA was $15.5 million, a slight decrease of 2% from the previous year. Knight also completed strategic acquisitions, including the Paladin Pharma Inc. business, and entered into exclusive license agreements with Sumitomo Pharma America Inc., expanding its product portfolio significantly.
The company made several strategic moves, such as securing a revolving credit facility with the National Bank of Canada and completing the acquisition of Paladin Pharma Inc. Knight also expanded its product offerings by acquiring over fifty products, including five pipeline and early launch stage assets, which are expected to drive future growth.
Looking ahead, Knight Therapeutics remains optimistic about its growth prospects, driven by its expanded product portfolio and strategic acquisitions. The company is well-positioned to continue its mission to acquire, in-license, develop, and commercialize pharmaceutical products in Latin America and Canada, with a focus on maintaining steady revenue growth and improving profitability.